Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings
Source: SeekingAlpha
2025-12-16 11:38:00 ET
More on Sarepta Therapeutics
- Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026
- FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat
- Sarepta Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Sarepta to refinance $291M of existing notes due 2027
- Sarepta a new outperform at Wedbush as selloff overdone
Read the full article on Seeking Alpha
For further details see:
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
-1.75% G/L:
$16.67 Last:
898,612 Volume:
$17.47 Open:
SRPT Latest News
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
